The effect of IGIF for expression of FasL in PBLs

H. Kohka; H. Iwagaki; T. Yoshino; I. Sakuma; T. Tanimoto; M. Kurimoto; N. Tanaka; K. Orita

The effect of IGIF for expression of FasL in PBLs

H. Kohka, H. Iwagaki, T. Yoshino, I. Sakuma, T. Tanimoto, M. Kurimoto, N. Tanaka, K. Orita

Research output: Contribution to journal › Article › peer-review

Abstract

Interferon-gamma inducing factor (IGIF) is a new cytokine which is thought to be useful clinically as an anti-tumor agent. Fas ligand (FasL) is a type II membrane protein belonging to the necrosis factor family, which induces apoptosis by binding to its counter receptor, Fas. In this paper, we report the effect of IGIF for the expression of Fas and FasL in human healthy peripheral blood lymphocytes (PBLs). IGIF up regulates the expression of Fas and FasL in PBLs.

Original language	English
Pages (from-to)	689-690
Number of pages	2
Journal	Biotherapy
Volume	11
Issue number	5
Publication status	Published - Jan 1 1997

Keywords

Fas/FasL
IGIF

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{135410d64ae84619b452b862ae4e054d,

title = "The effect of IGIF for expression of FasL in PBLs",

abstract = "Interferon-gamma inducing factor (IGIF) is a new cytokine which is thought to be useful clinically as an anti-tumor agent. Fas ligand (FasL) is a type II membrane protein belonging to the necrosis factor family, which induces apoptosis by binding to its counter receptor, Fas. In this paper, we report the effect of IGIF for the expression of Fas and FasL in human healthy peripheral blood lymphocytes (PBLs). IGIF up regulates the expression of Fas and FasL in PBLs.",

keywords = "Fas/FasL, IGIF",

author = "H. Kohka and H. Iwagaki and T. Yoshino and I. Sakuma and T. Tanimoto and M. Kurimoto and N. Tanaka and K. Orita",

year = "1997",

month = jan,

day = "1",

language = "English",

volume = "11",

pages = "689--690",

journal = "Biotherapy",

issn = "0914-2223",

number = "5",

}

TY - JOUR

T1 - The effect of IGIF for expression of FasL in PBLs

AU - Kohka, H.

AU - Iwagaki, H.

AU - Yoshino, T.

AU - Sakuma, I.

AU - Tanimoto, T.

AU - Kurimoto, M.

AU - Tanaka, N.

AU - Orita, K.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Interferon-gamma inducing factor (IGIF) is a new cytokine which is thought to be useful clinically as an anti-tumor agent. Fas ligand (FasL) is a type II membrane protein belonging to the necrosis factor family, which induces apoptosis by binding to its counter receptor, Fas. In this paper, we report the effect of IGIF for the expression of Fas and FasL in human healthy peripheral blood lymphocytes (PBLs). IGIF up regulates the expression of Fas and FasL in PBLs.

AB - Interferon-gamma inducing factor (IGIF) is a new cytokine which is thought to be useful clinically as an anti-tumor agent. Fas ligand (FasL) is a type II membrane protein belonging to the necrosis factor family, which induces apoptosis by binding to its counter receptor, Fas. In this paper, we report the effect of IGIF for the expression of Fas and FasL in human healthy peripheral blood lymphocytes (PBLs). IGIF up regulates the expression of Fas and FasL in PBLs.

KW - Fas/FasL

KW - IGIF

UR - http://www.scopus.com/inward/record.url?scp=0031008070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031008070&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031008070

SN - 0914-2223

VL - 11

SP - 689

EP - 690

JO - Biotherapy

JF - Biotherapy

IS - 5

ER -

The effect of IGIF for expression of FasL in PBLs

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this